Sign In

Communications of the ACM

ACM Opinion

Why Big Pharma Wants to Collect 2 Million Genomes

View as: Print Mobile App Share:
David Goldstein, Columbia

Geneticist David Goldstein will help the company to incorporate genetic sequences into better drug-development programmes.

Credit: AstraZeneca

Five months after announcing its intentions to gather genome sequences from 2 million people, pharmaceutical giant AstraZeneca has selected geneticist David Goldstein to head up the task.

From Nature
View Full Article



No entries found